All eyes will be on the European Commission on 11 March when it is due to unveil its proposal for a new Critical Medicines Act (CMA), a highly anticipated piece of legislation that industry has said it is fully behind but warned should not be rushed.
EU Critical Medicines Act Unveiling On 11 March–Industry Backs, But Urges Caution
The new act aims to tackle drug shortages and create a better framework for establishing manufacturing facilities of essential medicines in the EU. It should recognize differences between generics and innovative products, says industry group EUCOPE.
More from Distribution/Supply Chain
More from Geography
• By
Pink Sheet reporter and editors discuss the most recent senior staff departures at the FDA and their impact on the agency, as well as Commissioner Martin Makary’s plans for a new approval pathway and a combined adverse event database as outlined in an interview with a podcast host.
• By
The European Medicines Agency has recommended 16 drugs for EU-wide approval, including Vertex’s cystic fibrosis drug Alyftrek and five other orphans.
• By
The Pink Sheet highlights recent comments and insights from pharma officials and executives on key issues we are covering.